Royal Philips, the parent company of Philips Healthcare, has inked a $2.2 billion agreement to acquire Spectranetics, a vascular intervention equipment manufacturer.
Spectranetics' portfolio includes laser atherectomy catheters, its AngioSculpt and AngioSculptX scoring balloons, and its Stellarex drug-coated balloon. The company also makes leads for the removal of implanted pacemaker and cardioverter defibrillators, according to Philips.
The deal is expected to close in the third quarter of this year. Once it is completed, Spectranetics will become part of Philips' Image-Guided Therapy business group, Philips said.
